Merck Begins the P-III Clinical Evaluation of Bomedemstat to Treat Essential Thrombocythemia
Shots:
- Merck has initiated the patient enrollment globally for P-III (Shorespan-007) study assessing bomedemstat (oral, LSD1 inhibitor) vs hydroxyurea (SoC CT) to treat ET in patients (n=~300) not treated with cytoreductive therapy
- The 1EP includes durable clinicohematologic response rate (CHR); 2EPs are MFSAF v4.0 individual fatigue symptom item score, PROMIS Fatigue SF-7a total fatigue score & MFSAF v4.0 total symptom score, with other EPs as duration of hematologic remission, EFS & disease progression rate
- Bomedemstat is also being evaluated under P-III (Shorespan-006) study vs best available therapy for treating ET in patients (n=~300) with an inadequate response or intolerance to hydroxyurea
Ref: Merck | Image: Merck
Related News:- Merck Reports the Initiation of a Series of P-III Trials for Bomedemstat, Nemtabrutinib, MK-2870 and MK-5684 to Treat Solid Tumors
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
